US healthtech giant Boston Scientific’s pulmonary vein isolation (PVI) device trial has met its primary endpoint in patients ...

In that single-arm study, the rate of primary adverse events within 7 days of ablation was 2.9%, with the most common complication being pericardial tamponade (1.1%), and a few cases of stroke (0.7%) ...

Boston Scientific Corporation (NYSE: BSX) today announced data supporting the use of the FARAPULSE™ Pulsed Field Ablation ...

First phase of ADVANTAGE AF clinical trial achieves safety and effectiveness endpoints for treatment of drug ... defined as freedom from AF, atrial flutter, atrial tachycardia, re-ablation ...

episodes classified as atrial tachycardia. The AF Suppression Algorithm reduced symptomatic AF burden from 2.50% in the control group to 1.87% in the treatment group, a relative difference of 25%.

Indications for amiodarone treatment were categorized as the primary ... and 1/11 (9%) had paroxysmal atrial fibrillation as well as a wide complex tachycardia of which the differential diagnoses ...

Cite this: Progress in Paroxysmal Nocturnal Hemoglobinuria Treatment: The Impact of New Data From ASH 2024 - Medscape - Jan 02, 2025. Professor of Clinical Medicine, Jane Anne Nohl Division ...

The FDA approved a wide range of therapies in 2024, including many new molecular entities and biological products.